Expression of mdr1 and gst-π in human breast tumours: comparison to in vitro chemosensitivity

W.N. Keith, S. Stallard & R. Brown

CRC Department of Medical Oncology, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

Summary Increased expression of the mdr1 gene, encoding the 175 kDa P-glycoprotein, and the gst-π gene, encoding the anionic isozyme of glutathione S-transferase (GST), have previously been detected in continuous human breast cancer cell lines selected in vitro for resistance to doxorubicin. In this present study we have measured RNA levels of mdr1 and gst-π in primary human breast tumour biopsies prior to chemotherapy and from tumours which have different inherent responses to doxorubicin treatment, including colon, head and neck squamous cell carcinomas and myeloid leukaemias. Detectable levels of mdr1 mRNA was observed in 22 out of 49 breast tumours, with up to a 100-fold range in expression. A narrower range of gst-π expression has also been observed in these tumours. Chemosensitivity of cells grown in short-term culture from some of the breast tumours has been measured by an in vitro colony forming assay in the presence of doxorubicin. Comparison of the dose of doxorubicin causing 50% inhibition of growth (ID50) with RNA levels showed that the tumours with high mdr1 expression had high ID50, while the more sensitive explants had low mdr1 expression. These results support a role for mdr1 gene expression in determining the response of human breast cancer cells to chemotherapy.

Doxorubicin is known to be active against a range of solid tumours and is one of the best available agents in the treatment of breast cancer (Bonadonna et al., 1970; O'Bryan et al., 1973; Blum & Carter, 1974). However, both inherent and acquired resistance are in many cases major obstacles in successful treatment (O'Bryan et al., 1977). Increased levels of expression of the mdr1 gene, which codes for a 175 kDa plasma membrane associated glycoprotein, and the gst-π gene, encoding the anionic isozyme of glutathione S-transferase (GSTπ) have previously been shown in doxorubicin (adriamycin) resistant cell lines, derived by drug selection in culture (Kartner et al., 1985; Riordan et al., 1985; Scotto et al., 1986; Cowan et al., 1986; Deffe et al., 1988; Van der Blik et al., 1988). Many of these cell lines have been shown to be cross resistant to other chemotherapeutic agents such as Vinca alkaloids, anthracyclines and epipodophyllotoxins and have been termed multidrug resistant (MDR). The 175 kDa plasma membrane-associated protein, P-glycoprotein, has been suggested to increase resistance to a variety of drugs by increasing their efflux from the cell (Gerlach et al., 1986; Chen et al., 1986). GST isozymes have in common the ability to catalyse conjugation of drugs to reduced glutathione leading to drug detoxification (Jakoby, 1978).

A range of expression of mdr and gst-π has been shown in human tumour samples, both between tumours derived from different tissues and derived from the same tissue (Goldstein et al., 1989; Gerlach et al., 1987; Moscow et al., 1989). However, the relationship between levels of expression of mdr1 or gst-π and clinical drug resistance has yet to be fully elucidated. The identification of particular mechanisms of resistance in a tumour type is important for treatments designed to circumvent resistance (Raye, 1988). In this present study we have measured RNA levels of mdr1 and gst-π in untreated human breast tumour biopsies. We have compared the expression of these genes in breast cancer with other tumour types including colon tumours, head and neck squamous cell carcinomas and leukaemias, as well as cell lines selected for resistance to doxorubicin. We have also analysed epithelial cells grown during short term culture of breast tumour biopsies for in vitro sensitivity to doxorubicin, as measured by a colony forming assay (Smith et al., 1981a,b). The response of cells to doxorubicin compared to mdr1 and gst-π mRNA allows an indirect analysis of whether these mechanisms are involved in response of breast tumour cells to doxorubicin.

Materials and methods

RNA extraction from tumour biopsies

Tumour biopsies were frozen in liquid nitrogen immediately after surgical removal and were stored frozen at –70°C. All solid tumour samples were from patients who had not received any chemotherapy. Routine histology of the samples confirmed that the majority of the biopsy consisted of tumour cells. Solid tumours were pulsed whilst still frozen in a micro-dismembrator II (Braun, FRG) and DNA and RNA extracted by cell lysis and phenol/chloroform extraction (Kreig et al., 1983). Nucleated cells were isolated from the leukaemic samples by ficoll gradient centrifugation and RNA/DNA isolated as described above. DNA was removed from the samples by digestion with RNase-free DNase I (BCL, molecular biology grade). The quantity and quality of the RNA was initially assessed by the presence of ribosomal 28S and 18S RNA after electrophoresis in agarose.

Hybridisation probes

An mdr1 probe, mdr5A, which encodes about one-third of the coding region of a full-length mdr1 cDNA has previously been described (Ueda et al., 1987b). One µg of BamHI digested mdr5A was used as substrate for a riboprobe transcription kit (BCL) in the presence of uridine 5'-α-32P-triphosphate (30 TBq mmol⁻¹) from Amersham and SP6 polymerase. A full-length cDNA of gst-π, pGPI (Kano et al., 1987), was cloned into the EcoRI site of the polylinker of the riboprobe vector Bluescribe (Pharmacia). One µg of HindIII digested pGPI probe was used as substrate for riboprobe transcription as described above. The 7S probe (Balmain et al., 1982) was labelled with cytosine 5'-α-32P-triphosphate (111 TBq mmol⁻¹) from Amersham by nick translation and Poly d(T) probe was made by kinase labelling poly d(T)₂₀ oligonucleotide (Pharmacia) with adenosine 5'-γ-32P-triphosphate (111 TBq mmol⁻¹) from Amersham.

Hybridisation analysis

Northern hybridisation The RNA was electrophoresed in 1.4% agarose/6% formaldehyde gels and transferred to Gene Screen membranes (NEN/DuPont). Hybridisation was in 50% formamide buffer as previously described (Shen et al., 1986) for 16 h at 57°C with 5 x 10⁶ c.p.m. of synthetic RNA per ml. The filters were washed with 2 x SSC/0.1% SDS for 15 min at room temperature followed by two 20 min washes at 65°C with 0.1 x SSC/0.1% SDS. Autoradiograms were
exposed for 1–3 days. Amounts of RNA on the filters were quantified by reprobing the same filter with a probe for 7S RNA and intensity of signal measured by densitometrical scanning.

Dot blot hybridisation  Gene screen filters were presoaked in 0.25 M di-sodium phosphate buffer and 15, 5, 1.6 and 0.5 µg of total RNA applied. After baking, prehybridisation, hybridisation and washing were performed exactly as described above for the Northern hybridisation experiments. Amounts of RNA on the filters were quantified by reprobing the same filter with a kinase labelled poly d(T) oligomer as previously described (Harley, 1987). Repeat identical RNA from tumours, MDR cell lines and their parental drug sensitive cell lines which had a range of both mdr1 and gst-π expression were analysed on all filters to allow comparison between experiments. Autoradiograms were exposed overnight and intensity of signals were quantified using densitometrical scanning.

Colony forming assay for doxorubicin sensitivity of breast tumour outgrowths

Sensitivity of breast cells to doxorubicin was assessed using the short-term colony forming assay described by Smith et al. (1981a, 1985). Tumour tissue was minced and disaggregated in medium containing 200 U µl⁻¹ collagenase (Worthington). Resultant ductal alveolar structures and clumps of cells were plated onto plastic and allowed to grow for 7–10 days. Growth was supported in nutrient medium F10/DMEM supplemented with 10⁻⁵ M oestradiol, 10 µg ml⁻¹ insulin, 5 µg ml⁻¹ transferrin and 5 mg ml⁻¹ epidermal growth factor. Outgrowths were then trypsinised, counted and plated onto mitomycin C (4 mg ml⁻¹) treated STO mouse fibroblast feeder layers. They were then exposed to a range of eight concentrations of doxorubicin (from 5 × 10⁻⁴ M to 3.4 × 10⁻¹¹ M) for 24 h. Drug was removed, the nutrient medium replaced and surviving colonies counted after 2 weeks. Sensitivity was determined by the amount of drug required to kill 50% of the control untreated cells (ID₅₀). Greater detail of this assay and analysis of a large number of breast tumours will be published separately (S. Stallard, in preparation).

Results

mdr1 mRNA levels in human tumours

RNA prepared from human tumours and cell lines were analysed by dot-blot hybridisation using the same conditions of stringency that detect specific 4.5 kb mdr1 mRNA transcripts and 0.7 kb gst-π transcripts in Northern hybridisations. Typical dot-blots and Northern hybridisations using each probe are shown in Figure 1. Of 49 primary breast tumour biopsies from untreated patients, 23 samples had measurable levels of mdr1 mRNA (Figure 2). High levels of mdr1 mRNA were also detected in one breast tumour lymph node biopsy. The levels of mdr1 mRNA in some of these tumours reached levels equivalent to that detected in cell lines selected for drug resistance in vitro. Signal intensity of 20 µg RNA from the cell lines MCF-7ADR (Cowan et al., 1986), A2780AD (Rogan et al., 1984) and H69LX10 (an adriamycin resistant cell line isolated from a human lung cell line, P. Twentaman, personal communication) had values of 90, 160 and 100 respectively. Dot blot hybridisations contained RNAs from the adriamycin resistant cell line, H69LX10 and the parental drug sensitive line, H69, as well as repeat samples of the tumour RNAs to allow comparison between hybridisation experiments as described in the Materials and methods. Undetectable and very low signal intensities were given an arbitrary value of 1. Biopsy samples from untreated colon tumours all showed detectable mdr1 mRNA. The range of mdr1 levels in the colon tumours overlapped with about 20% of the breast tumour samples. Of fourteen untreated squamous cell carcinomas of the head and neck, eight had measurable levels of mdr1 mRNA. Detectable mdr1 mRNA was also present in three out of five untreated acute myeloid leukaemia (AML) samples. The chronic myeloid leukaemia (CML) samples shown represent sequential samples from the same patient. The sample with undetectable mdr1 RNA was taken prior to chemotherapy, while the sample with detectable expression was taken after anthracycline based chemotherapy.

gst-π mRNA levels in human tumours

Figure 3 shows the gst-π mRNA levels detected in the same tumour samples as shown in Figure 2. Signal intensity of 20 µg RNA from the cell lines MCF-7ADR (Cowan et al., 1986), A2087AD (Rogan et al., 1984) and H69LX10 (an adriamycin resistant cell line isolated from a human lung cell line, P. Twentaman, personal communication) had values of 60, 55 and 10 respectively. Dot blot hybridisations contained RNAs from the adriamycin resistant cell line, H69LX10 and the parental drug sensitive line, H69, as well as repeat samples of the tumour RNAs to allow comparison between hybridisation experiments as described in the Materials and methods. Undetectable and very low signal intensities were given an arbitrary value of 1. All the breast tumour samples, with the exception of one, showed low or undetectable levels of gst-π mRNA. On the other hand all of the colon tumours, with the exception of one, showed relatively high levels of transcripts. The leukaemia samples generally had low levels of gst-π, including the sequential CML samples taken during chemotherapy. A large proportion of squamous cell carcinomas of the head and neck had high levels of gst-π mRNA levels.
Comparison of mdr1 and gst-π mRNA levels to in vitro sensitivity of cell outgrowths of breast tumours

Comparison of doxorubicin ID₅₀ to mdr1 and gst-π mRNA level is shown in Figure 4 for 14 breast tumour biopsies and two normal breast tissue biopsies. No sample which is relatively sensitive to doxorubicin was observed to have high mdr1 or gst-π mRNA level. All of the samples with high mdr1 levels have relatively high ID₅₀ for doxorubicin. The level of mdr1 expression weakly correlates with ID₅₀ to doxorubicin with a Pearson correlation coefficient (r) of 0.46 (P < 0.1). These observations support a role of mdr1 expression in response of epithelial cells derived from breast tumours to doxorubicin.

No significant correlation between ID₅₀ to doxorubicin and gst-π expression using the Pearson correlation test was observed. Each individual tumour sample has been numbered in Figure 4 to allow comparison between mdr1 and gst-π expression. Sample number 13 showed high levels of mdr1 and gst-π expression. Comparison between mdr1 and gst-π mRNA levels in all the breast samples assayed shows a low level of correlation which is only slightly significant (r = 0.48, P < 0.1). Thus for some of these tumours coexpression of mdr1 and gst-π may be occurring, as has been observed for adriamycin resistant MCF7 breast cell lines (Cowan et al., 1986).

Discussion

Doxorubicin is widely used in the treatment of advanced breast cancer, with an overall response rate among breast cancer patients of about 55% (Blum & Carter, 1974; O'Bryan et al., 1977). This means that almost half the patients are resistant to doxorubicin from the outset of treatment. A better understanding of the mechanisms underlying this resistance should lead to improved therapeutic results. Drug delivery studies in breast cancer patients suggest that defective delivery of adriamycin into breast tumours is unlikely to be a major factor (Stallard et al., 1990). Increased mdr and gst-π expression have been detected in continuous human breast cancer cell lines selected in vitro for resistance to doxorubicin (Cowan et al., 1986; Moscow et al., 1988). Several lines of evidence support the involvement of mdr1 expression in resistance of tumours to chemotherapy: (a) full-length cDNAs for the mdr1 gene transfected (Ueda et al., 1987a) or infected (Guild et al., 1988) into cells confer multi-drug resistance; (b) tumour types which are clinically drug resistant, such as colon, generally have elevated mdr1 mRNA levels (Goldstein et al., 1989; Fojo et al., 1987b); (c) cell lines from tumours with elevated mdr1 mRNA levels have a multi-
drug resistant phenotype which is reversible by inhibitors of the multidrug transporter such as verapamil and quinidine (Fojo et al., 1987a); (d) immunocytochemical staining for P-glycoprotein expression correlates with \textit{in vitro} sensitivity to doxorubicin of tumour tissue from patients (Salmon et al., 1989).

We have detected \textit{mdrl} mRNA in 25 out of 49 primary breast tumour biopsies from untreated patients. Detectable \textit{mdrl} expression has also been observed in one out of three lymph node biopsies. In these untreated tumours a hundred fold range in expression of \textit{mdrl} has been observed with some samples reaching the levels observed in resistant cell lines selected \textit{in vitro}. Levels of \textit{mdrl} expression in about 20% of the breast tumour samples are equivalent to the levels we detect in intrinsically chemoresistant colon tumours. These results support a possible involvement of \textit{mdrl} expression in response to chemotherapy of some breast tumours.

\textit{In vitro} chemosensitivity to doxorubicin of epithelial cells grown from breast tumour biopsies showed that no sample which is relatively sensitive to doxorubicin was observed to have high \textit{mdrl} or \textit{gst-\textpi} mRNA level. All of the samples with high \textit{mdrl} levels have relatively high ID50 for doxorubicin. These observations are supportive of a role for \textit{mdrl} expression in limiting the response of breast cells to doxorubicin. A number of tumour samples however are relatively resistant to doxorubicin, yet have low levels of \textit{mdrl} expression. In these tumours alternative resistance mechanisms may be effective. Increased expression of \textit{gst-\textpi} co-expressed with \textit{mdrl}, has been observed in some doxorubicin resistant breast tumour cells (Cowan et al., 1986). With one exception, we have detected low levels of \textit{gst-\textpi} mRNA in the breast tumour samples. No large differences in expression levels were detected and no significant correlation with doxorubicin sensitivity of outgrowths was observed. However, it is still possible that \textit{gst-\textpi} expression may have a role in chemoresponsiveness of a subset of breast tumours. A weak correlation exists between expression of \textit{mdrl} and \textit{gst-\textpi} in the breast tumour samples we have analysed, suggesting that common mechanisms may be involved in their expression.

Our results show that \textit{mdrl} expression can be detected in approximately half of the breast tumours analysed and that explants from tumours with high \textit{mdrl} expression are relatively more resistant to doxorubicin \textit{in vitro}. These results are in agreement with those of Salmon et al. (1989), who recently showed that five out of 13 breast tumours stained positively with a P-glycoprotein antibody and that all five of these tumours were ‘resistant’ using a short-term \textit{in vitro} assay of doxorubicin sensitivity. Goldstein et al. (1989) have found detectable levels of \textit{mdrl} mRNA in nine of 57 untreated breast tumour biopsies. However, Merkel et al. (1989) found no \textit{mdrl} mRNA in 53 untreated breast tumour samples. The differences in proportions of tumours with detectable \textit{mdrl} mRNA may be due to technical variations in sensitivity of the hybridisation conditions used. The stringent hybridisation conditions used in this present study detect only the \textit{mdrl} specific 4.5 kb mRNA and appropriate positive and negative control RNAs were included in hybridisation experiments. However, the differences in detection of \textit{mdrl} mRNA may also represent variations in \textit{mdrl} expression in tumours from different geographical locations. Exposure to carcinogens has been shown in animal model carcinogenesis systems to affect levels of \textit{mdrl} expression (Gottesman, 1988). Differences in proportions of tumours with detectable \textit{mdrl} expression may reflect variations in tumour aetiology and carcinogen exposure in different geographical locations. We have also detected \textit{mdrl} expression in squamous cell carcinomas of the head and neck and in samples from AML patients. All of these samples were from patients who had not received chemotherapy.

Direct evidence for involvement of \textit{mdrl} expression in clinical response of tumours to chemotherapy would require a prospective clinical trial. Drug resistance in multidrug resistant cell lines can be overcome \textit{in vitro} using agents such as verapamil and quinidine which are thought to act by competitively binding to the P-glycoprotein (Safa, 1988). High expression of P-glycoprotein in breast tumours suggest that trials using such reversing agent in conjunction with chemotherapy may be appropriate for breast cancer. For some drugs, such as quinidine, the levels which are clinically achievable are equivalent to those which are effective \textit{in vivo} and a controlled clinical trial in breast cancer using quinidine is underway in our department.

We would like to thank Drs M. Gottesman and I. Pastan (NIH, Bethesda) for making available to us the plasmid MDR5a and Dr M. Muramatsu (University of Tokyo, Tokyo) for the plasmid GP1. We are also very grateful to a number of surgeons and pathologists in Glasgow for helping with the collection of tumour samples, including Prof. D. George, Drs A.-M. McNicol, C. Meardle, G. Smith, D. Souter, A. MacKay, C. MacKay and I. Brown and also Dr C. Marshall (Chester Beauly Laboratories, London) for the AML samples. We would also like to thank Prof. S.B. Kaye and Dr I. Freshney for very useful discussion. This work was supported by the Cancer Research Campaign.

References

BALMAIN, A., KRUMLAUF, R., VASS, J.K. & BIRNIE, G.D. (1982). Cloning and characterisation of the abundant cytotoxic plasmid 75 RNA from mouse cells. \textit{Nucl. Acids Res.}, 10, 425.

BONADONNA, G., MORFARDINI, S., DE LENA, M., FOSSATI-BELLANI, F. & BERETTA, G. (1970). Phase 1 and preliminary phase II evaluation of Adriamycin. \textit{Cancer Res.}, 30, 2572.

BLUM, R.H. & CARTER, S.K. (1974). Adriamycin – a new antitumour drug with significant clinical activity. \textit{Ann. Intern. Med.}, 80, 249.

CHEN, C.J., CHIN, J.E., UEDA, K. & MYERS, C.E. (1986). Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen induced resistance to xenobiotics in rats. \textit{Proc. Natl Acad. Sci. USA}, 83, 9328.

DEFFIE, A.M., ALAM, T., SENEVIRATNE, C. & 5 others (1988). Multifactorial resistance to Adriamycin. \textit{Cancer Res.}, 48, 3595.

FOJO, A.T., SHEN, D.W., MICKLEY, L.A., PASTAN, I. & GOTTESMAN, M.M. (1987a). Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug resistance gene. \textit{J. Clin. Oncol.}, 5, 1922.

FOJO, A., UEDA, K., SLAMON, D.J., POPPLACK, D.G., GOTTESMAN, M.M. & PASTAN, I. (1987b). Expression of a multidrug resistance gene in human tumours and tissues. \textit{Proc. Natl Acad. Sci. USA}, 84, 265.

GERLACH, J.H., BELL, D.R., KARAKOUSIS, C. & 5 others (1987). P-glycoprotein in human sarcoma: evidence for multidrug resistance. \textit{J. Clin. Oncol.}, 5, 1452.

GERLACH, J.H., ENDICOTT, J.A., JURANKA, P.F. & 4 others (1986). Homology between P-glycoprotein and a bacterial hemolysin transport protein suggests a mode for multidrug resistance. \textit{Nature}, 324, 485.

GOLDSTEIN, L.J., GALSKI, H., FOJO, A. & 11 others (1989). Expression of a multidrug resistance gene in human cancers. \textit{J. Natl Cancer Inst.}, 81, 116.

GOTTESMAN, M.M. (1988). Multidrug resistance during chemical carcinogenesis: A mechanism revealed? \textit{J. Natl Cancer Inst.}, 80, 1351.

GUILD, B.C., MULLIGAN, R.C., GROS, P. & HOUSMAN, D.E. (1988). Retrovirial transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. \textit{Proc. Natl Acad. Sci. USA}, 85, 1595.

HARLEY, C.B. (1987). Hybridisation of oligo (dT) to RNA on nitrocellulose. \textit{Gene Anal. Tech.}, 4, 17.

EXPRESSION OF \textit{mdrl} AND \textit{gst-\textpi} 715
KANO, T., SAKAI, M. & MURAMATSU, M. (1987). Structure and expression of a human class \( \pi \) glutathione S-transferase messenger RNA. *Cancer Res.*, 47, 5620.

KARTNER, N. EVERNADER-PORELLA, E., BRADLEY, G. & LING, V. (1985). Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. *Nature*, 316, 820.

KAYE, S.B. (1988). The multidrug resistance phenotype. *Br. J. Cancer*, 58, 691.

KRIEG, P., ANTMANN, E. & SAUER, G. (1983). The simultaneous extraction of high molecular weight DNA and of RNA from solid tumours. *Ann. Biochem.*, 134, 288.

MERKEL, D.E., FUQUA, S.A.W., TANDON, A.K., HILL, S.M., BUZDAR, A.V. & MCGUIRE, W.L. (1989). Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or amplification. *J. Clin. Oncol.*, 7, 1129.

MOSCOW, J.A., FAIRCHILD, C.R., MADDEN, M.J. & 7 others (1989). Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumours. *Cancer Res.*, 49, 1422.

MOSCOW, J.A., TOWNSEND, A.J., GOLDSMITH, M.E. & 7 others (1988). Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. *Proc. Natl Acad. Sci. USA*, 85, 6518.

O'BRYAN, R.M., BAKER, L.H., GOTTLEIB, J.E. & 6 others (1977). Dose response evaluation of adriamycin in human neoplasia. *Cancer*, 39, 1940.

O'BRYAN, R.M., LUCE, J.K., TALLEY, R.W., GOTTLEIB, J.A., BAKER, L.H. & BONADONNA, G. (1973). Phase II evaluation of adriamycin in human neoplasia. *Cancer*, 32, 1.

RIORDAN, J.R., DEUCHARTS, K., KARTNER, N., ALAN, N., TRENT, J. & LING, V. (1985). Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. *Nature*, 316, 817.

ROGAN, A.M., HAMILTON, T.C., YOUNG, R.C., KLECHER, R.W. & OZOLS, R.F. (1984). Reversal of adriamycin resistance by verapamil in human ovarian cancer. *Science*, 224, 994.

SAFA, A.R. (1988). Photoaffinity labeling of the multidrug resistance related P-glycoprotein with photoactive analogs of verapamil. *Proc. Natl Acad. Sci. USA*, 85, 7187.

SALMON, S.E., GORGA, T.M., MILLER, T., SCHEPER, R. & DALTON, W.S. (1989). Prediction of doxorubicin resistance in vitro in myeloma, lymphoma and breast cancer by P-glycoprotein staining. *J. Nail Cancer Inst.*, 81, 696.

SCOTTO, K.W., BIEDLER, J.L. & MELERA, P.W. (1986). Amplification and expression of genes associated with multidrug resistance in mammalian cells. *Science*, 232, 751.

SHEN, D.W., FOJO, A., CHIN, J.E. & 4 others (1986). Human multidrug-resistant cell lines: increased mdrl expression can precede gene amplification. *Science*, 232, 643.

SMITH, H.S., HACKETT, A., LAN, S. & STAMPFER, M.R. (1981a). Use of an efficient method for culturing human mammary epithelial cells to study adriamycin sensitivity. *Cancer Chemother. Pharmacol.*, 6, 237.

SMITH, H.S., LAN, S., CERIANI, R., HACKETT, A.J. & STAMPFER, M.R. (1981b). Clonal proliferation of cultured nonmalignant and malignant human breast epithelia. *Cancer Res.*, 41, 4637.

SMITH, H.S., LIPPMAN, M.E., HILLER, A.J., STAMPFER, M.R. & HACKETT, A.J. (1985). Response to doxorubicin of cultured normal and cancerous human mammary epithelial cells. *J. Nail Cancer Inst.*, 74, 341.

STALLARD, S., MORRISON, J.G., GEORGE, W.D. & KAYE, S.B. (1990). Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy. *Cancer Chemother. Pharmacol.*, 25, 286.

UEDA, K., CASDARELLI, C., GOTTESMAN, M.M. & PASTAN, I. (1987a). Expression of a full length cDNA for the human mdrl gene confers resistance to colchicine, doxorubicin and vinblastine. *Proc. Natl Acad. Sci. USA*, 84, 3004.

UEDA, K., CLARK, D.P., CHEN, C.-J., RONINSON, I.B., GOTTESMAN, M.M. & PASTAN, I. (1987b). The human multidrug resistance (mdrl) gene. *J. Biol. Chem.*, 262, 505.

VAN DER BLIEK, A.M., BAAS, T., VAN DER VELDE-KOERTS, T. & 6 others (1988). Genes amplified and overexpressed in human multidrug-resistant cell lines. *Cancer Res.*, 48, 5927.